PROBLEM TO BE SOLVED: To provide Sp35 antibody and utilization thereof associated with molecules and methods for treatment of neurological diseases, disorders and injuries such as spinal cord injury.SOLUTION: This technology is based on a discovery that Sp35 (Sp35 is also designated in the literature as LINGO-1 and LRRN6) is expressed in oligodendrocytes and neuronal cells and negatively regulates oligodendrocytes/neuronal differentiation, survival and axon myelination. Furthermore, certain antagonists of Sp35 promote survival, proliferation and differentiation of oligodendrocytes and neuronal cells. Based on these discoveries, the technology is generally involved in antibodies, antigen binding fragment or derivatives thereof which can be used as an antagonist of Sp35. Additionally, the technology is generally involved in methods for treating various diseases, disorders or injuries associated with demyelination, demyelinization, oligodendrocyte/neuronal cell death or axonal injury by the administration of an Sp35 antagonist antibody or antigen binding fragment.
Sp35 ANTIBODY AND USE THEREOF